Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

DNTH·NASDAQ

$84.97

-1.5%
HealthcareBiotechnology

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$3.55B
EPS-4.2000
P/E Ratio-9.59
Earnings Date08/06/2026

dnth

Net Interest Income

Last Annual Value

16.12M

3-Year CAGR

141%

5-Year CAGR

%

10-Year CAGR

%

Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Competitors Analysis of Net Interest Income

DNTH · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
16.12M
50.1%176.4%N/A 
11.34M
440.1%N/AN/A
ANAB logo
AnaptysBio, Inc.
NASDAQ:ANAB
-66.39M
N/AN/AN/A
-15.75M
N/AN/AN/A
16.01M
10.2%273.6%N/A
3.85M
-27.1%41.6%N/A
16.52M
71.3%N/AN/A
9.16M
N/AN/AN/A
316.00K
N/A9.0%N/A
Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. Fair Value Envelope

DNTH · NASDAQ

Our analysis suggests that DNTH has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.97, this represents a potential HIDDEN relative to our calculated worth for Dianthus Therapeutics, Inc..

Intrinsic Value
Current Price: $84.97